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Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being recognized as a systemic
inflammatory disorder. Psoriatic arthritis is a well-known comorbidity of psoriasis. A rapidly expanding body of
literature in various populations and settings supports additional associations between psoriasis and cardiome-
tabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders. The
pathogenesis of comorbid disease in patients with psoriasis remains unknown; however, shared inflammatory
pathways, cellular mediators, genetic susceptibility, and common risk factors are hypothesized to be contributing
elements. As additional psoriasis comorbidities continue to emerge, education of health care providers is essential
to ensuring comprehensive medical care for patients with psoriasis. ( J Am Acad Dermatol 2017;76:377-90.)
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Learning objectives
After completing this learning activity, participants should be able to list at least five comorbidities that are associated with psoriasis, and discuss the supporting evidence and identify
psoriasis patients who have the greatest risk of developing cardiovascular disease.
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INTRODUCTION
Psoriasis is a common chronic inflammatory
disease that affects [7.5 million people in the
United States and approximately 125 million people
worldwide.1-3 It has significant impacts on both
physical and emotional health-related quality of life
comparable to other major illnesses.4 In the last
decade, tremendous progress has been made in
furthering our understanding of the genetics,
pathophysiology, and treatment of psoriasis.
Epidemiologic and basic scientific evidence contrib-
uting to our knowledge of the natural history and
biology of psoriasis, respectively, have led to the
recognition of psoriasis as a disorder with important
health implications that extend beyond the skin.
The first observation of comorbid disease among
patients with psoriasis was made in 1897 when
Strauss5 reported an association between psoriasis
and diabetes. In 1961, Reed et al6 described a high
prevalence of heart disease including coronary throm-
bosis and myocardial infarction (MI) in postmortem
examinations of psoriasis patients with psoriatic
arthritis (PsA). Subsequently, in 1978, McDonald
et al7 observed an increased prevalence of venous
and arterial vascular disease in hospitalized
patients with psoriasis. Now many years later, a
quickly evolving body of literature using modern
epidemiologic techniques has shown that psoriasis,
particularly severe disease, is associated with
increased mortality8 and comorbid disease burden9,10
that are hypothesized to be the result of chronic
inflammation associated with the skin disease.
We review the epidemiologic data supporting
associations between psoriasis and cardiometabolic
diseases, gastrointestinal diseases, kidney disease,
malignancy, infection, mood disorders, PsA, and
other emerging comorbid diseases. Recognition of
the comorbid disease burden associated with psori-
asis is essential for comprehensive medical care for
patients with this chronic skin disorder.
CARDIOMETABOLIC DISEASE
Key points
d Cardiometabolic disease is prevalent among
patients with psoriasis, especially those with
more severe skin disease
d Psoriasis may be an independent risk factor
for diabetes and major adverse cardiovascu-
lar events; the risk of a major adverse
cardiovascular event is greatest among those
with severe psoriasis
d Chronic systemic, specifically vascular, inflam-
mation may be increased in patients with
psoriasis and may contribute to atherogenesis
Major adverse cardiovascular events
Cardiovascular (CV) risk factors are prevalent
among patients with psoriasis, and therefore an
increased risk of CV disease (CVD) may be expected.
However, in 2006, a large, population-based cohort
study in the United Kingdom found that psoriasis
was associated with an increased risk of MI, inde-
pendent of traditional risk factors, such as body mass
index (BMI), smoking, hypertension, diabetes, and
dyslipidemia.11 Moreover, a dose-response effect
was shown, with stronger, more clinically significant
risk in patients with more severe disease as defined
by receipt of phototherapy or systemic therapies
indicated for severe psoriasis. Subsequently,
numerous epidemiologic studies have similarly sug-
gested psoriasis to be an independent risk factor for
MI, stroke, and death caused by CVD, collectively
termed major adverse cardiovascular events
(MACE). While a few studies have reported non-
statistically significant associations between psoriasis
and MACE,12-15 as discussed in detail elsewhere,16-18
results from these studies remain consistent with the
larger body of work that have found statistically
significant associations. To date, many of the studies
have been summarized in $1 of 8 meta-analyses of
psoriasis and CVD (Table I).19-26 Two meta-
analyses19,25 specifically examined the risks of MI,
stroke, and CV mortality according to psoriasis
severity and reported the greatest risks to be among
those with severe disease. Risk of MI among patients
Abbreviations used:
BMI: body mass index
BSA: body surface area
CAD: coronary artery disease
CD: Crohn’s disease
CEC: cholesterol efflux capacity
CHD: coronary heart disease
CKD: chronic kidney disease
CTCL: cutaneous T-cell lymphoma
CV: cardiovascular
CVD: cardiovascular disease
ESRD: end-stage renal disease
FDG: fluorodeoxyglucose
FRS: Framingham Risk Score
HDL: high-density lipoprotein
IBD: inflammatory bowel disease
IHD: ischemic heart disease
MACE: major adverse cardiovascular events
MI: myocardial infarction
NAFLD: nonalcoholic fatty liver disease
NASH: nonalcoholic steatohepatitis
NMSC: nonmelanoma skin cancer
OR: odds ratio
PET/CT: positron emission tomography/
computed tomography
PsA: psoriatic arthritis
RA: rheumatoid arthritis
RR: relative risk or risk ratio
UC: ulcerative colitis
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with mild psoriasis was found to be significantly
increased in bothmeta-analyses,19,25 albeit to a lesser
extent, suggesting that CV risk is not limited to those
with severe disease. Longer duration of psoriasis has
also been associated with increased risk of CVD.27,28
Collectively, these data provide evidence for psori-
asis as an independent risk factor for CVD.
Additional analyses have identified the clinical
importance of and provided practical measures for
the increased risk of MACE associated with psoria-
sis.29,30 In a cohort study of severe psoriasis patients
in the United Kingdom, Mehta et al29 found the
attributable risk of severe psoriasis on MACE over a
10-year period to be 6.2%. Importantly, in a study to
determine the impact of psoriasis on the
Framingham Risk Score (FRS), adding psoriasis to
the FRS resulted in reclassification of a majority of
patients to a higher CV risk category whereby 73% of
patients at low risk were reclassified as intermediate
risk and 53% of patients at intermediate risk were
reclassified as high risk.31 Putting the psoriasis-
associated CV risk into context with other chronic
inflammatory diseases, Ahlehoff et al30 found the
increased risk of MACE associated with severe pso-
riasis to be nearly identical to that conferred by
diabetes alone. Similarly, a single observational
study of patients with either rheumatoid arthritis
(RA) or psoriasis suggests that patients treated with
similar systemic treatments (eg, methotrexate) each
have similarly elevated risks of MACE, independent
of traditional risk factors.32
Shared pathophysiologic pathways between
psoriasis and CVD, including chronic type 1 helper
(TH1) T cell- and TH17-mediated inflammation,
33-38
monocyte and neutrophil modulation,39-41 increased
oxidative stress,35 endothelial cell dysfunction,42
increased uric acid,43,44 angiogenesis,35 and
increased circulating microparticles45-48 may explain
the increased CVD risk associated with psoriasis. In
addition, persistent pathophysiologic processes that
drive psoriasis (eg, epidermal hyperproliferation,
inflammation,49,50 and angiogenesis) may also exert
pleiotropic adverse effects on the CV system that
contribute to atherogenesis. Mouse models of
psoriasis have shown that chronic skin-specific
inflammation has systemic effects, including arterial
hypertension,51 endothelial dysfunction,51 and
vascular inflammation and thrombosis.38 Studies in
psoriasis patients yield similarly consistent findings
using [18F]-fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography
(PET/CT), a sensitive tool for measuring vascular
inflammation and visualizing macrophage activity
in vivo. Aortic inflammation measured by PET/CT is
a predictor of future CV events and has been shown
to rapidly decrease when patients are exposed to
interventions known to lower CV risk (ie, statin
therapy), making it an attractive surrogate endpoint
to study.52 Aortic inflammation has been observed to
be increased in psoriasis patients in a manner that is
independent of CV risk factors and correlates with
severity of skin disease,53 lending further support to
the idea that inflammatory pathways in psoriasis
exert systemic effects. Lastly, common genetics
between psoriasis, diabetes, and CVD, such as
CDKAL1, ApoE4, and others, have been sug-
gested,54-64 and genes relevant to metabolic disease
and CVD have been found to be dysregulated
in lesional skin and in the serum of psoriasis
patients.64-66 On the other hand, other work suggests
that shared genetic pathways are unlikely to explain
the association between psoriasis and CVD.67
Obesity
Obesity is an independent risk factor for psoriasis.
In studies of incident psoriasis,68-70 the risk of pso-
riasis was found to increase with higher BMI.69 A
meta-analysis of 16 observational studies found a
pooled odds ratio (OR) for the association between
psoriasis and obesity to be 1.66 (95% confidence
interval [CI], 1.46-1.89; Table II).71 Among studies that
accounted for psoriasis severity, generally defined by
treatment patterns, the pooled ORs for the associa-
tion between obesity and mild and severe psoriasis
were 1.46 (95% CI, 1.17-1.82) and 2.23 (95% CI, 1.63-
3.05), respectively. As further support for a relation-
ship between psoriasis severity and obesity, Langan
et al72 performed a cross-sectional study of patients
with psoriasis in the United Kingdom for whom
information on body surface area (BSA) involvement
by psoriasis was available and found a positive dose-
dependent relationship between objective measures
of psoriasis severity and obesity.72
Hypertension
Hypertension is more prevalent among patients
with versus without psoriasis. A meta-analysis of 24
observational studies found a pooled OR for the
association between psoriasis and hypertension to
be 1.58 (95% CI, 1.42-1.76).73 The odds of hyperten-
sion among patients with psoriasis increased with
greater disease severity with ORs of 1.30 (95% CI,
1.15-1.47) for mild and 1.49 (95% CI, 1.20-1.86) for
severe psoriasis as defined by treatment patterns.42
Two cohort studies also observed psoriasis to be
associated with an increased risk of incident
hypertension.74,75
Importantly, studies of patients with hypertension
suggest more severe hypertension and poorly
controlled blood pressure among patients with
J AM ACAD DERMATOL
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Table I. Summary of systematic reviews and meta-analyses assessing the association between psoriasis and major adverse cardiovascular events
Study Study dates No. of studies
Total no. of patients
OutcomePsoriasis No psoriasis Composite measure of association (95% CI)
Armstrong et al19
(2013)
January 1, 1980 to
January 1, 2012
9 Mild: 201,239
Severe: 17,415
9,914,799 MACE: MI, stroke,
and CV mortality MI
Mild psoriasis: RR 1.29 (1.02-1.63) Severe psoriasis:
RR 1.70 (1.32-2.18)
Stroke
Mild psoriasis: RR 1.12 (1.08-1.16) Severe psoriasis:
RR 1.56 (1.32-1.84)
CV mortality
Mild psoriasis: RR 1.03 (0.86-1.25) Severe psoriasis:
RR 1.39 (1.11-1.74)
Gaeta et al20
(2013)
NR 13 1,862,297 43,407,300 CV risk: MI,
vascular disease,
and mortality
Overall CV risk
RR 1.24 (1.18-1.31)
MI
RR 1.24 (1.11-1.39)
Vascular disease
RR 1.27 (1.12-1.43)
Mortality
RR 1.41 (0.97-2.04)
Gu et al21
(2013)
1966 to October
2012
15 Total (psoriasis + no psoriasis):
6,230,774
MI, stroke, CVD,
and CV mortality
MI
RR 1.32 (1.13-1.55)
Stroke
RR 1.26 (1.12-1.41)
CVD
RR 1.47 (1.30-1.60)
CV mortality
RR 1.33 (1.00-1.77)
Horreau et al22
(2013)
1980 to December
211
33 324,650 5,309,087 MI, CAD, and stroke MI
RRdcohort: 1.25 (1.03-1.52); cross-sectional: 1.57 (1.08-2.27)
CAD
RRdcohort: 1.20 (1.13-1.27); case-control: 1.84 (1.09-3.09);
cross-sectional: 1.19 (1.14-1.24)
Stroke
Cohort: 1.02 (0.92-1.14); cross-sectional: 1.14 (1.08-1.19)
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Miller et al23
(2013)*
Before October
25, 2012
75 503,686 29,686,694 CVD, IHD,
cerebrovascular
disease, and CV
mortality
CVD
OR 1.4 (1.2-1.7)
IHD
OR 1.5 (1.2-1.9)
Cerebrovascular disease
1.1 (0.9-1.3)
CV mortality
0.9 (0.4-2.2)
Pietrzak et al24
(2013)
1960 to 2011 14 367,358 9,199,656 CV events: MI, IHD,
cerebral ischemic
stroke, and sudden
cardiac death
OR 1.28 (1.18-1.38)
Samarasekera
et al25 (2013)
1974 to 2012 14 All: 488,315
Mild: 327,418
Severe: 12,854
10,024,815 MI, stroke, and
CV mortality MI
All psoriasis:
HR/IRR 1.40
(1.03-1.89)
Mild psoriasis:
HR/IRR 1.34
(1.07-1.68)
Severe psoriasis:
HR/IRR 3.04
(0.65-14.35)
Stroke
All psoriasis:
HR/IRR 1.13
(1.01-1.26)
Mild psoriasis:
HR/IRR 1.15
(0.98-1.35)
Severe psoriasis:
HR/IRR 1.59
(1.34-1.89)
CV mortality
All psoriasis: NR Mild psoriasis:
SMR 1.03
(0.86-1.25)
Severe psoriasis:
SMR 1.37 (1.17-1.60);
HR 1.57 (1.26-1.96)
Xu et al26
(2012)
Database inception
to March 2012
7 326,598 5,230,048 Composite of
MI and stroke
Composite
RR 1.20 (1.10-1.31)
MI
RR 1.22 (1.05-1.42)
Stroke
RR 1.21 (1.04-1.40)
CAD, Coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; IHD, ischemic heart disease; IRR, incidence rate ratio; MACE, major adverse
cardiovascular event; MI, myocardial infarction; OR, odds ratio; RR, relative risk or risk ratio.
*Systematic review and meta-analysis of the association between psoriasis and CVD and cardiovascular risk factors. Total numbers of studies and patients included are as reported in the full
systematic review and meta-analysis, a subset of which is specifically relevant to psoriasis and CVD.
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Table II. Summary of systematic reviews and meta-analyses assessing the association between psoriasis and cardiovascular disease risk factors
Study Study dates
Total no. of patients
No. of studies included CV risk factor
Composite measure of association
(95% CI)Psoriasis No psoriasis
Armstrong et al71 (2012) January 1, 1980 to January 1,
2012
201,831 2,119,329 Total: 16
Severity assessment: 5
Incidence: 1
Obesity Overall: OR 1.66 (1.46-1.89);
mild: OR 1.46 (1.17-1.82);
severe: OR 2.23 (1.63-3.05);
incidence: HR 1.18 (1.14-1.23)
Armstrong et al73 (2012) January 1, 1980 to January 1,
2012
309,469 2,384,229 Total: 24
Severity assessment: 5
Incidence: 2
Hypertension Overall: OR 1.58 (1.42-1.76);
mild: OR 1.30 (1.15-1.47);
severe: OR 1.49 (1.20-1.86);
incidence: HR 1.09
(1.05-1.14); incidence:
RR 1.17 (1.06-1.30)
Armstrong et al78 (2012) January 1, 1980 to January 1,
2012
404,494 4,640,847 Total: 27
Severity assessment: 5
Incidence: 5
Diabetes Overall: OR 1.59 (1.38-1.83);
mild: OR 1.53 (1.16-2.04);
severe: OR 1.97 (1.48-2.62);
incidence: RR 1.27 (1.16-1.40)
Ma et al81 (2012)y January 1, 1980 to January 1,
2012
265,685 2,167,198 Total: 25
Severity assessment: 5
Incidence: 1
Dyslipidemia Overall OR: 1.04-5.55;
mild OR: 1.10-3.38;
severe OR: 1.26-5.55
Armstrong et al89 (2013) January 1, 1980 to January 1,
2012
41,853 1,357,324 Total: 12
Severity assessment: 3
Metabolic syndrome Overall OR: 2.26 (1.70-3.01);
mild OR: 1.22 (1.11-1.35)*;
moderate OR: 1.56 (1.38-1.76)*;
severe OR: 1.98 (1.62-2.43)*
CI, Confidence interval; CV, cardiovascular; HR, hazard ratio; OR, odds ratio; RR, relative risk.
*Reported from single study by Langan et al.72
ySystematic review only.
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psoriasis compared with those without psoriasis.76,77
In addition, the likelihood of poorly controlled
hypertension appears to increase with more severe
skin disease, independent of BMI and other risk
factors.77
Diabetes
Psoriasis is associated with an increased risk of
diabetes, independent of traditional risk factors. A
meta-analysis of 5 cohort studies assessing the risk of
incident diabetes among patients with psoriasis
found a pooled relative risk (RR) for diabetes of
1.27 (95% CI, 1.16-1.40).78 The risk of diabetes and
likelihood of insulin resistance and diabetic
complications are suggested to increase with greater
psoriasis severity as defined by treatment patterns
or BSA affected, respectively, independent of
traditional risk factors, such as BMI.9,72,79 Moreover,
diabetic patients with psoriasis appear to be more
likely to require pharmacologic management79 and
suffer from micro- and macrovascular diabetes com-
plications than diabetic patients without psoriasis.80
Dyslipidemia
Dyslipidemia may be more prevalent among
patients with than without psoriasis. In a systematic
review, 20 of 25 included studies found significant
associations between psoriasis and dyslipidemia,
with ORs ranging from 1.04 to 5.55.81 Among 3 of
the studies included in the systematic review, the
ORs for dyslipidemia ranged from 1.10 to 3.38 for
patients with mild psoriasis and from 1.36 to 5.55 for
patients with severe psoriasis. The directionality of
the association between the 2 conditions remains
unclear; some studies suggest dyslipidemia may be a
risk factor for developing psoriasis.82,83
Advanced lipid testing techniques have shown a
more atherogenic lipid profile and decreased high
density lipoprotein (HDL) cholesterol efflux capacity
(CEC) among patients with versus without psoriasis,
beyond CV risk factors.84,85 Increasing psoriasis
severity is negatively correlated with HDL CEC in
both adults and children with psoriasis.85,86 HDL
CEC is also directly related to coronary artery disease
burden in patients with psoriasis87 and is suggested
to be an important proxy for vascular disease.
Metabolic syndrome
Metabolic syndrome is generally defined by the
presence of a combination of central obesity, hyper-
tension, insulin resistance, and dyslipidemia.88 Studies
have found metabolic syndrome and its individual
components tobemoreprevalent amongpatientswith
than without psoriasis in both adult and pediatric
populations.89,90 A meta-analysis of 12 observational
studies found a pooled OR of 2.26 (95% CI, 1.70-3.01)
for the association between psoriasis and metabolic
syndrome, but the analysiswas limitedby thepresence
of publicationbias due to an absence of smaller studies
in the published literature.89 Importantly, in Langan
et al’s cross-sectional study72 in the United Kingdom,
the prevalence of metabolic syndrome correlated
directly with BSA affected by psoriasis.
GASTROINTESTINAL DISEASE
Key points
d Psoriasis may be associated with an
increased incidence and prevalence of in-
flammatory bowel disease, particularly
Crohn’s disease
d Few studies suggest that psoriasis is associ-
ated with an increased prevalence of hepatic
diseases, particularly nonalcoholic fatty liver
disease
Inflammatory bowel disease
Common genetic and inflammatory pathways
have been implicated in psoriasis and IBD, which
includes Crohn’s disease (CD) and ulcerative colitis
(UC).59,91-94 The epidemiology of this relationship
remains poorly defined. Several studies have
observed increased prevalence and incidence of
IBD among patients with psoriasis95,96 and vice
versa,97-99 with varying degrees of association, and
a Taiwanese study suggested an absence of associ-
ation.10 Cohen et al95 observed that psoriasis may be
more strongly associated with CD than UC (ORs 2.49
[95% CI, 1.71-3.62] and 1.64 [95% CI, 1.15-2.23],
respectively). Similarly, a cohort study of US women
found an increased risk of CD among patients with
psoriasis (RR, 3.86 [95% CI, 2.23-6.67]), while the risk
of UC was attenuated and not statistically significant
(RR, 1.17 [95% CI, 0.41-3.36]).96
Hepatic disease
Nonalcoholic fatty liver disease (NAFLD) is a
common chronic liver disease in Western industrial-
ized countries100 and encompasses a spectrum of
liver disorders from mild hepatic steatosis to
nonalcoholic steatohepatitis (NASH). Associations
between psoriasis and NAFLD have been reported
in the literature. In a meta-analysis of 7 observational
studies that were considered low tomoderate quality
and, for the most part, did not adjust for potential
confounding factors, such as metabolic syndrome,
NAFLD was found to be more prevalent among
patients with versus without psoriasis (pooled OR,
2.15 [95% CI, 1.57-2.94]).101 Beyond NAFLD, a cross-
sectional study in the United Kingdom found that
psoriasis was associated with a higher prevalence of
J AM ACAD DERMATOL
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‘‘mild’’ liver disease, including chronic hepatitis,
alcoholic liver disease, and NAFLD (OR, 1.41 [95%
CI, 1.12-1.76]).9 A positive dose-response relation-
ship between psoriasis severity based on BSA
involvement and ‘‘mild’’ liver disease was also seen.
CHRONIC KIDNEY DISEASE
Key points
d Moderate to severe psoriasis may be an
independent risk factor for chronic kidney
disease and end-stage renal disease
d The odds of chronic kidney disease increase
in a dose-dependent manner with greater
psoriasis severity
The term ‘‘psoriatic nephropathy’’ was first
introduced based on case reports of glomerulone-
phritides in patients with psoriasis.102 Until recently,
most studies assessing the association between
psoriasis and kidney disease have been small and
cross-sectional, with varying results. In a UK cohort
study of cause-specific mortality among patients with
psoriasis, severe psoriasis was associated with a
4-fold increased risk of death from nephritic or
nonhypertensive kidney disease.103 A Swedish
cohort study also found mild psoriasis to be
associated with more than a 2-fold increased risk of
death from kidney disease.104 In 2013, another UK
cohort study found that severe psoriasis may, in fact,
be a risk factor for chronic kidney disease (CKD) and
end-stage renal disease (ESRD), independent of
traditional risk factors, such as age, sex, BMI,
CVD, diabetes, hypertension, hyperlipidemia, and
nephrotoxic medications (hazard ratio [HR] for CKD
1.93 [95% CI, 1.79-2.08]; HR for ESRD, 4.15 [95% CI,
1.70-10.11]).105 A nested cross-sectional analysis of
patients with psoriasis for whom information on BSA
involvement was available found the prevalence of
CKD to increase in a dose-dependent manner with
more severe psoriasis. A cohort study in Taiwan
similarly found severe psoriasis to be associated with
nearly 2- and 3-fold increased risks of CKD and
ESRD, respectively.106
MALIGNANCY
Key points
d Psoriasis, particularly severe disease, may be
associated with an increased risk of cancer
d Lymphoma has been most consistently asso-
ciated with psoriasis, and risk of cutaneous
T-cell lymphoma is suggested to be the
highest
Patients receiving treatments for severe psoriasis
have a 41% increased risk of dying from malignancy
than patients without psoriasis.103 Risk of malig-
nancy attributable to psoriasis itself remains uncer-
tain. A meta-analysis of 11 observational studies
evaluating the risk of malignancy among patients
with psoriasis suggested that overall risk of cancer,
excluding nonmelanoma skin cancers (NMSCs), is
increased (standardized incidence ratio, 1.16 [95%
CI, 1.07-1.25]).107 Greater risks of upper aerodiges-
tive tract, respiratory tract, liver, pancreas, urinary
tract cancers, and lymphoma were also suggested.107
The level of heterogeneity among the included
studies was high, making interpretation challenging.
In addition, many studies did not account for
important confounding factors, such as smoking
and drinking, or assess psoriasis treatment effects
on the risk of subsequent malignancy, calling into
question the validity of attributing the increased risk
of cancer to psoriasis alone. A subsequent cohort
study of cancer risk among patients with psoriasis in
the United Kingdom that included information on
BMI, smoking, and drinking also found increased
risks of lung cancer, NMSC, and lymphoma, support-
ing some of Pouplard et al’s findings.108 The greatest
risks of cancer were among those receiving
treatments for severe psoriasis. The association be-
tween psoriasis and lung cancer was lost, however,
after stratification by smoking status. Additional
studies109-111 assessing lymphoma risk in patients
with psoriasis also found persistently increased risks
of lymphoma (1.3- to 2-fold increased risk) even
among those without a history of immunosuppres-
sive therapy, although absolute risks remained low.
Of the specific lymphoma types, the association
between psoriasis and cutaneous T-cell lymphoma
(CTCL) was suggested to be the strongest.108,111 It
remains unclear what role psoriasis therapies or
misdiagnosis of CTCL as psoriasis may play in
explaining this observation.
INFECTION
Key points
d Streptococcal pharyngitis is a trigger of gut-
tate psoriasis, and exacerbation of psoriasis
in the setting of HIV infection is known
d Psoriasis may be associated with an
increased risk of serious infection (ie, infec-
tion requiring hospitalization), especially
respiratory infections
Infection is the second-leading cause of excess
death among patients who are receiving therapies for
severe psoriasis, and patients with severe psoriasis
have a 65% increased risk of dying from infection
than patients without psoriasis.103 With the advent of
targeted biologic therapies, much attention has been
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paid tomeasuring the risk of infection associatedwith
these therapies for psoriasis. However, infection risk
attributable to psoriasis itself remains poorly under-
stood. The most well-recognized association be-
tween psoriasis and infection is that of guttate
psoriasis and streptococcal pharyngitis, which is
thought to be caused by molecular mimicry between
streptococcal M peptides and human keratins.112,113
Exacerbation of psoriasis in the setting of HIV
infection has also been documented.114,115 The risk
of serious infection among patients with psoriasis has
only more recently been evaluated.116,117 A Dutch
cohort study found psoriasis to be independently
associated with an increased risk of serious infection
(HR, 1.54 [95% CI, 1.44-1.65]) whereby the greatest
risk was among patients with severe psoriasis as
defined by treatment patterns (HR, 1.81 [95%CI, 1.57-
2.08]).116 Respiratory tract, abdominal, and skin in-
fections were the most common infections among
patients with psoriasis. Similarly, a cohort study in
Taiwan reported an increased risk of hospitalized
pneumonia among patients with psoriasis, indepen-
dent of other potential risk factors for pneumonia
(HR, 1.40 [95% CI, 1.12-1.73]). Severe psoriasis was
associated with the greatest risk of hospitalized
pneumonia (HR, 1.68 [95% CI, 1.12-2.52]).117 While
neither study had access to information on potential
confounders, such as obesity, smoking, anddrinking,
subsequent cohort studies in the United Kingdom
that included this information confirmed that psori-
asis is associated with an increased risk of serious
infection118 including hospitalized pneumonia,119
and further suggested that this risk may increase
with greater BSA involvement by psoriasis.
MOOD DISORDERS
Key points
d Mood disorders are common among patients
with psoriasis
d Psoriasis is associated with an increased risk
of depression, anxiety, and suicidal ideation
Psoriasis has a major impact on patients’ physical
and emotional health-related quality of life compa-
rable to other major illnesses,4 and this may predis-
pose patients to the development of mood disorders,
such as depression, anxiety, and suicidality. Mood
disorders, particularly depression, have been sug-
gested to bemore prevalent in patients with psoriasis
than in the general population (up to 62% preva-
lence).120 In a meta-analysis of 98 mostly cross-
sectional studies examining the association between
psoriasis and depression, patients with psoriasis had
more depressive symptoms (pooled standardized
mean difference, 1.16 [95% CI, 0.67-1.66]) and were
nearly 1.6-fold more likely to experience depression
(pooled OR, 1.57 [95% CI, 1.40-1.76]) than patients
without psoriasis.120
The risk of depression in psoriasis has been
evaluated in 2 cohort studies. In a UK study, psoriasis
was found to be associated with increased risks of
depression (HR,1.39 [95%CI, 1.37-1.41]), anxiety (HR,
1.31 [95% CI, 1.29-1.34]), and suicidality (HR, 1.44
[95% CI, 1.32-1.57]).121 The risk of depression was
greatest amongpatientswhowere receiving therapies
for severe psoriasis (HR, 1.72 [95% CI, 1.57-1.88]).
Similarly, a study of women in the Nurses’ Health
Study122 foundpsoriasis to be associatedwith a nearly
30% increased risk of depression (RR, 1.29 [95% CI,
1.10-1.52]), independent of age, BMI, lifestyle factors,
and comorbid conditions.
PSORIATIC ARTHRITIS
Key points
d Psoriatic arthritis is an inflammatory
arthritis that is present in 6% to 42% of
patients with psoriasis
d Psoriatic arthritis is more prevalent among
patients with more extensive skin disease
d Approximately 15% of patients with psoria-
sis have undiagnosed psoriatic arthritis
Psoriatic arthritis (PsA) is the most well-
recognized comorbidity of psoriasis and is a hetero-
geneous inflammatory arthritis characterized by joint
or entheseal inflammation and extra-articular mani-
festations.123 The prevalence of inflammatory
arthritis in patients with psoriasis ranges from 6% to
42% depending on the definitions used and popula-
tions studied.124-137 The prevalence of PsA increases
with greater psoriasis severity124,132,138 and dura-
tion124,139; however, the severity of skin disease is
only weakly associated with severity of joint disease.
PsA has been associated with the distribution of
psoriasis involvement (ie, scalp, intergluteal, and
perianal)140 and the presence of nail dystrophy,
which is suggested to indicate early entheseal
inflammation.123,140,141
The diagnosis of PsA can be especially
challenging. The differential diagnosis includes
osteoarthritis, RA, crystal arthropathy (eg, gout or
calcium pyrophosphate disease), and fibromyal-
gia.123,142-146 Undiagnosed PsA among patients
with psoriasis seen in the dermatology setting is
prevalent and estimated at 15.5%.147 PsA generally
occurs after the onset of psoriasis141,147 and can be
progressive and result in permanent joint damage.
Therefore, early detection is essential because early
treatment improves outcomes.123,148,149 The varied
clinical features of and classification criteria for PsA
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and its associations with cardiometabolic and other
comorbid diseases are reviewed elsewhere.123,150
EMERGING COMORBIDITIES
Key point
d Other emerging comorbidities of psoriasis
include chronic obstructive pulmonary dis-
ease, peptic ulcer disease, sexual dysfunc-
tion, and obstructive sleep apnea
Additional epidemiologic studies have suggested
associations between psoriasis and other emerging
comorbid conditions, including chronic obstructive
pulmonary disease,9,151,152 peptic ulcer disease,9,153
sexual dysfunction,154 and obstructive sleep ap-
nea,155-157 among others. Further characterization
of known comorbidities and identification of new
comorbid disease associations with psoriasis are
anticipated as research efforts continue.
In summary, it is essential for both clinicians and
patients to recognize the potentially heightened risk
of CVD and other comorbidities associated with
psoriasis that may increase with greater disease
severity and duration. Particularly as psoriasis
remains largely undertreated,158,159 the disease re-
mains active for decades in most patients, potentially
placing them at increased risk for associated comor-
bidities and mortality. Patient and provider educa-
tion and increased awareness of psoriasis
comorbidities are critical to improving the care and
quality of life for those living with psoriasis.
The authors thank Jina Chung, MD, for her early
contributions to the preparation of the manuscript.
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